In lung and prostate cancer, SPRY4 showed tumour suppressor activity19,20, whereas in ovarian cancer, knockdown of SPRY4 attenuated growth factor-induced cancer progression21. This evidence concerns the gene SPRY4 and prostate carcinoma.